Shriram Properties Targets ₹600 Crore Revenue from New Bengaluru Housing Project
Source: Economictimes
Arth Insight · What this means for your wallet
- If you're eyeing a home in Bengaluru, this adds a new large mid-to-premium option to your choices within the next year.
- For property owners in Bengaluru, strong developer interest like this can underpin property values due to continued market demand.
- Increased supply from large projects could influence overall property price trends and rental yields in Bengaluru's key areas.
Real estate major Shriram Properties has signed a joint development deal for a 9.1-acre land parcel in Bengaluru. The residential project is expected to generate significant revenue and is scheduled for launch within the current financial year.
- ▸Shriram Properties is developing a 9.1-acre residential project in Bengaluru.
- ▸The project is expected to bring in over ₹600 crore in revenue.
- ▸The development will cover a total area of 6.7 lakh square feet.
- ▸The official launch is scheduled for the current financial year (FY25).
- ✓Shriram Properties is developing a 9.1-acre residential project in Bengaluru.
- ✓The project is expected to bring in over ₹600 crore in revenue.
- ✓The development will cover a total area of 6.7 lakh square feet.
- ✓The official launch is scheduled for the current financial year (FY25).
Shriram Properties, a leading name in the South Indian real estate market, has announced a significant expansion of its residential portfolio in Bengaluru. The company has officially signed a joint development agreement for a sprawling 9.1-acre land parcel, marking another milestone in its growth strategy within the Karnataka capital.
Project Scale and Financial Outlook
The upcoming residential development is projected to be a major revenue driver for the company. Shriram Properties expects the project to generate a total revenue exceeding ₹600 crore. This financial projection reflects the strong demand for quality housing in Bengaluru’s evolving real estate landscape.
The project will feature a total developable area of approximately 6.7 lakh square feet. While specific details regarding the configuration of units are yet to be finalized, the scale suggests a mid-to-premium residential complex aimed at urban professionals and families.
Strategic Timeline and Launch
The company is moving swiftly to capitalize on the current market momentum. According to the official announcement, Shriram Properties plans to launch the project within the 2024-25 financial year. This quick turnaround from land acquisition to launch highlights the company's focus on operational efficiency and its commitment to maintaining a steady pipeline of inventory.
What This Means for Homebuyers and Investors
For potential homebuyers in Bengaluru, this announcement signals the arrival of a new, large-scale residential option backed by a reputable brand. For shareholders of Shriram Properties, the ₹600 crore revenue potential strengthens the company's financial outlook for the coming years.
- Location Advantage: While the specific micro-market in Bengaluru hasn't been named, the 9.1-acre size allows for significant amenities and open spaces.
- Growth Strategy: The use of a joint development model allows the company to expand its footprint while managing capital expenditure effectively.
- Market Confidence: This move underscores continued developer confidence in Bengaluru’s residential sector despite global economic fluctuations.
This report is for informational purposes only; real estate investments carry market risks, and revenue projections are subject to regulatory approvals and market volatility.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
When can I book a flat in this new Shriram project?
The company plans to launch the project within the current financial year (FY24-25), at which point bookings will likely open.
Where exactly in Bengaluru is this project located?
The specific neighborhood has not been disclosed yet, but the project will be built on a 9.1-acre land parcel.
How much revenue is Shriram Properties expecting from this deal?
The company expects to generate more than ₹600 crore in total revenue from this residential development.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Related Stories
CCI Clears Advent International's ₹3,150 Crore Investment in Yatharth Hospitals
The Competition Commission of India (CCI) has approved Advent International's substantial ₹3,150 crore investment in Yatharth Hospitals through its affiliate, Rasmalai Limited. This deal will grant Advent a 24.9% minority stake in the healthcare provider. Yatharth Hospitals plans to utilize these funds for its expansion efforts and to enhance its healthcare network, buoyed by strong operational revenues and profit growth.
BreakingPiramal Pharma Slashes China Reliance to Under 10% for Supply Chain Resilience
Piramal Pharma has significantly reduced its dependence on Chinese raw materials to less than 10%. This strategic move aims to enhance supply chain resilience against geopolitical risks, with the company expanding its manufacturing footprint to India, the UK, and the US.
Dr Reddy's Pivots to Generic Semaglutide, Biosimilars for Future Growth
Dr Reddy's Laboratories is strategically focusing on the relaunch of generic semaglutide and expanding its biosimilars portfolio to drive future growth. This comes as the company navigates mixed results, with domestic formulations business growing but North American Revlimid sales declining in the September quarter.
Aayush Wellness Launches Calcium & Vitamin D Tablets, Enters ₹1.35 Lakh Crore Bone Health Market
Aayush Wellness Limited has launched new calcium and vitamin D tablets, marking its entry into India's significant bone and joint health segment. This expansion reflects the growing consumer demand for preventive healthcare and nutritional supplements designed to support musculoskeletal health.